ContraVir Pharmaceuticals (NASDAQ:CTRV) has been given a $4.00 price target by investment analysts at Maxim Group in a research report issued to clients and investors on Monday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock.
Separately, ValuEngine raised shares of ContraVir Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd.
ContraVir Pharmaceuticals (NASDAQ CTRV) traded up $0.01 during trading on Monday, hitting $0.25. 394,400 shares of the stock were exchanged, compared to its average volume of 823,082. ContraVir Pharmaceuticals has a fifty-two week low of $0.23 and a fifty-two week high of $1.96. The stock has a market capitalization of $19.71, a price-to-earnings ratio of -0.51 and a beta of 1.92.
ContraVir Pharmaceuticals Company Profile
ContraVir Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of targeted antiviral therapies with three candidates in the pipeline. Two of its antiviral candidates for treating hepatitis B include Phase IIa clinical candidate TXL, a novel potent analog of antiviral drug tenofovir and decreased systemic exposure, thereby potentially reducing renal and bone side effects; and CRV431, a next generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against hepatitis B virus.
Receive News & Ratings for ContraVir Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.